Towards Better Control in CKD: Improving Anemia Management

ANNA CE Satellite Symposium - New Orleans, Louisiana, October 17, 2004

Welcome, Introduction and Program Overview


Lesley C. Dinwiddie, MSN, RN, FNP, CNN


David B. Van Wyck, MD
Please make sure that all slide images load before starting the lecture

Windows Media Player
If the slides don't move during play, click on the media player icon, maximize the player, click on Tools-Options-Security, and check "Run script commands when present".
Option 1 Streaming Server
Option 2 For slow connections, right click on preload icon and choose "save target as". Play file from saved location.

Real Audio Player
Option 3 Streaming, Firewall-friendly
Option 4 Preload (2-5 mB)

Audio FAQ
For problems and suggestions, please click on this link.
This satellite symposium is sponsored by an unrestricted educational grant from American Regent Laboratories, Inc. This activity has been planned and produced in accordance with CE guidelines and policies. From a CE symposium held on October 17, 2004 at the American Nephrology Nurses' Association (ANNA) Fall Meeting in New Orleans, LA. This symposium was approved by ANNA. It was not part of the official ANNA Annual Meeting.
This activity has been awarded 1.5 contact hours by the American Nephrology Nurses Association (ANNA) which is accredited as a provider and approver of continuing education in nursing by the American Nurses Credentialing Center-Commission on Accreditation (ANCC-COA).
Posting Date: January, 2005
CE Credit Eligible Through: May, 2006
CE Credit Hours/Completion Time: 1.5
Target Audiences: Nurses, nurse practitioners, and other healthcare professionals who treat and manage patients with CKD.
Method of participation: Listen to the talk, read the PubMed abstracts linked to data slides and talk references, take the post-test, read the linked abstracts in the post-test answer feedback material.
LEARNING OBJECTIVES:
After participating in this program, the participant should be able to:
  1. Describe the benefits of anemia management in chronic kidney disease (CKD).
  2. Outline the results of a U.S. clinical trial of iron sucrose and erythropoietin in the treatment of anemia in CKD.
  3. Appraise the characteristics of available parenteral iron products.
  4. Explain the critical role of the nephrology nurse in anemia management.
SPEAKER DISCLOSURE STATEMENT:
Speaker is a member of the Speakers Bureau for American Regent Laboratories Inc.

ANNA and HDCN CE POLICY STATEMENTS:
The CE policy and disclosure statements of the American Nephrology Nurses' Association are given in detail on the Symposium Home Page. The CE policy statements of HDCN are listed on this page.

Moderator:
It is now my very, very great pleasure to introduce Dr. David Van Wyck. He is no stranger to us. He is a professor of medicine and surgery at the University of Arizona College of Medicine in Tucson, and he is chair of the K/DOQI Anemia Work Group. Dr. Van Wyck earned his medical degree at the University of Arizona College of Medicine. Then, he undertook a research fellowship in surgical biology, and completed both his residency in internal medicine and fellowship in nephrology. Dr. Van Wyck has written or contributed to books, book chapters, articles, and abstracts on basic iron metabolism and reticuloendothelial function, and on clinical aspect of iron and anemia in patients with chronic kidney disease. He pursues active research in anemia and iron deficiency in patients with chronic kidney disease, and he regularly reviews manuscripts for the major nephrology journals. Dr. Van Wyck served on the K/DOQI anemia work group that developed evidence-based clinical practice guidelines for the treatment of chronic renal failure. He assumed chair responsibilities in 2002. Frequently invited to speak, Dr. Van Wyck has lectured on issues in anemia and iron management, protocol development in the treatment of dialysis-associated anemia, and new approaches to iron and erythropoietin replacement therapy. Please help me welcome Dr. Van Wyck as he produces for better control in CKD improving anemia management.

Dr. Van Wyck:
It is a pleasure to be back here. The last time I was at this meeting was in my hometown, Phoenix, Arizona, a couple of hours in Savannah for the spring meetings. Those are fun.

We are here today to talk about anemia, my favorite topic. We are talking about anemia today with a twist. Joel is going to talk about issues of anemia management that are beyond the detail. I am going to talk about some new information about iron, its structure and chemistry, and some of the implications of that for clinical practice. Michelle Turgeon is here from the management perspective to talk on a unique topic, which is managing anemia management. I think that has probably never been done before.


Next Talk (Joel D. Glickman)


This satellite symposium is sponsored by an unrestricted educational grant from American Regent Laboratories, Inc.
This activity has been planned and produced in accordance with CE guidelines and policies. From a CE symposium held on October 17, 2004 at the American Nephrology Nurses' Association (ANNA) Fall Meeting in New Orleans, LA.
This symposium was approved by ANNA. It was not part of the official ANNA Annual Meeting.


BACK TO
TOPIC INDEX :